An ASCO preview: What to watch for at cancer research’s big meeting - Takeaways - MDSpire

An ASCO preview: What to watch for at cancer research’s big meeting

  • By

  • Adam Feuerstein

  • May 28, 2026

  • 0 min

Share

  • 1

    The ASCO annual meeting will feature key presentations, including Revolution Medicines' daraxonrasib for advanced pancreatic cancer.

  • 2

    Daraxonrasib showed a median overall survival of 13.2 months, significantly higher than the 6.7 months for standard chemotherapy.

  • 3

    Akeso's ivonescimab will present results from the Phase 3 HARMONi-6 study, focusing on newly diagnosed squamous non-small cell lung cancer.

  • 4

    Investor expectations for ivonescimab include a 20%-30% reduction in the risk of death compared to tislelizumab.

  • 5

    Bristol Myers Squibb will report results from the Phase 3 SUCCESSOR-2 study of mezigdomide in multiple myeloma at ASCO.

Original Source(s)

An ASCO preview: What to watch for at cancer research’s big meeting

  • by Adam Feuerstein

  • May 28, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry